INTEGRILIN PACKAGE INSERT PDF

ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS. 1 INTEGRILIN is indicated for the prevention of early myocardial infarction in adults presenting. Package leaflet: Information for the patient. Integrilin mg/ml solution for infusion eptifibatide. Read all of this leaflet carefully before you start using this. 1. Package leaflet: Information for the patient. Eptifibatide Accord 2 mg/ml solution for injection eptifibatide. Read all of this leaflet carefully before you start using.

Author: Malami Kajisho
Country: Trinidad & Tobago
Language: English (Spanish)
Genre: Health and Food
Published (Last): 27 May 2012
Pages: 101
PDF File Size: 19.72 Mb
ePub File Size: 7.71 Mb
ISBN: 934-5-88914-120-8
Downloads: 20950
Price: Free* [*Free Regsitration Required]
Uploader: Moogudal

There has been no clinical experience in patients dependent on dialysis. These studies revealed no evidence of harm to the fetus due to eptifibatide. Inhibition of platelet aggregation 15 min after bolus.

Platelet aggregation usually returns to normal within 4—8 hours after discontinuing therapy.

Maximal inhibition of platelet aggregation integriliin within 15 minutes following IV administration and is rapidly reversible. Unmet therapeutic needs in the management of acute ischemia.

Dilution Eptifibatide – Integrilin ® – GlobalRPH

There was no apparent difference in efficacy between older and younger patients treated with Eptifibatide Injection. Table 5 also shows the incidence of the components of the primary endpoint, death whether or not preceded by an MI and new MI in surviving patients at 30 days.

Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. Patients Overall incidence of major bleeding 9. Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the integilin and abdominal areas of monkeys. Percutaneous Coronary Intervention PlavixclopidogrelAngiomaxbivalirudineptifibatidecangrelorMore Handbook on injectable drugs.

Adjunct to anticoagulant therapy insery. Usual Diluents Administer directly from vial. Bleeding was classified as major or minor by the criteria of the TIMI study group. By clicking Subscribe, I agree to the Drugs.

  CATALOGO BTICINO LIVING 2012 PDF

The potential for development of antibodies to eptifibatide has been studied in subjects. Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses. The structural formula is:.

Integrilin

Aspirin, to mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. The pxckage common bleeding complications were related to cardiac revascularization CABG-related or femoral artery access site bleeding.

There was no apparent difference in efficacy between older and younger patients treated with Integrilin. Has been used as an adjunct to thrombolytic therapy e.

Heparin in acute coronary disease-requiem for a heavyweight? Marcel Dekker, Inc; WB Saunders Company; A risk-benefit assessment of abciximab in angioplasty. The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the Integrilin infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. A target aPTT of 50 to 70 seconds was recommended.

Treatment with Eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization i. Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Targeted approaches to thrombus formation: In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation 2- to 3-fold of the bleeding time.

Heart Attack PlavixBrilintaaspirinlisinoprilmetoprololatenololMore To view content sources and attributions, please refer to our editorial policy. Guidelines for managing patients with unstable angina: Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure.

  ENTRE VISILLOS GAITE PDF

Disclaimer The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. If bleeding cannot be controlled with pressure, infusion of eptifibatide and concomitant heparin should be stopped immediately. Acute Coronary Syndrome ———————— Aspirin to mg orally initially and daily thereafter.

This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Goa KL, Noble S. Pursuing progress in acute coronary syndromes. Plasma integrulin half-life is approximately 2. Aspirin versus heparin to prevent myocardial infarction during the acute knsert of unstable angina. Role of platelets in restenosis after percutaneous coronary revascularization. This was a “real world” study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country.

The potential for development of antibodies to eptifibatide has been studied in subjects. Use contraindicated in patients with hepatic disease severe enough to paxkage synthesis of coagulation factors.

Clinical pharmacology of eptifibatide. The majority of patients received aspirin mg once daily. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Eptifibatide Ihtegrilin is a clear, colorless, sterile, non-pyrogenic solution for intravenous IV use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of